Comparative Pharmacology
Head-to-head clinical analysis: NUMORPHAN versus SYNALGOS DC A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUMORPHAN versus SYNALGOS DC A.
NUMORPHAN vs SYNALGOS-DC-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist; binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
SYNALGOS-DC-A contains dihydrocodeine, which is a semisynthetic opioid agonist; aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes; and caffeine, a central nervous system stimulant. Dihydrocodeine binds to mu-opioid receptors in the central nervous system to produce analgesia. Aspirin irreversibly acetylates COX-1 and COX-2, reducing prostaglandin synthesis. Caffeine enhances analgesia via adenosine receptor antagonism and possibly by increasing drug absorption.
Intravenous or subcutaneous: 0.5-2 mg (0.1-0.2 mg/kg for severe pain) every 2-3 hours as needed; not to exceed 20 mg/day.
1-2 capsules orally every 4-6 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours in adults; prolonged to 3–4 hours in elderly and up to 15 hours in patients with severe hepatic impairment.
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours; clinical context: prolonged with hepatic impairment, age >60 years, and renal dysfunction; accumulation of norpropoxyphene may cause cardiotoxicity
Primarily renal (approximately 70% as unchanged drug, <5% as noroxymorphone and other conjugates); biliary/fecal excretion accounts for ~20%.
Renal: ~70-80% as free and conjugated propoxyphene; norpropoxyphene is renally eliminated; biliary: 10-20%; fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic